The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often viewed as outdated and hindering progress, https://adamxutk790029.wikicommunication.com/5858597/pot_rescheduling_a_expansion_catalyst